Eliem Therapeutics logo

Eliem TherapeuticsNASDAQ: ELYM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 August 2021

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$256.17 M
-61%vs. 3y high
57%vs. sector
-vs. 3y high
-vs. sector
-61%vs. 3y high
44%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$3.82-$0.01(-0.13%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ELYM Latest News

Eliem Therapeutics Reports Second Quarter Financial Results
globenewswire.com14 August 2024 Sentiment: POSITIVE

Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents of approximately $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for budoprutug SEATTLE and CAMBRIDGE, United Kingdom, Aug. 14, 2024 (GLOBE NEWSWIRE) --  Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem” or the “Company”), today reported financial results for the quarter ended June 30, 2024 and provided a business update. “Following the close of the Tenet Medicines acquisition and the concurrent financing, we believe Eliem is well-positioned as we transition to becoming a leading development stage immunology company,” said Dr. Aoife Brennan, CEO of Eliem.

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
seekingalpha.com28 June 2024 Sentiment: POSITIVE

Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia.

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
globenewswire.com28 June 2024 Sentiment: POSITIVE

SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of the Russell stock indexes, effective today.

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
globenewswire.com27 June 2024 Sentiment: POSITIVE

Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy

Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
Zacks Investment Research21 July 2023 Sentiment: POSITIVE

Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.

Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
InvestorPlace20 July 2023 Sentiment: POSITIVE

Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. Eliem Therapeutics came to this decision after completing a review of the company and its various programs.

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself
Market Watch20 July 2023 Sentiment: POSITIVE

Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal excitability disorders, said it is exploring its strategic options. The Seattle and Cambridge, U.K.-based company said it has halted the development of its Kv7 program, which was focused on treatments for pain and epilepsy.

What type of business is Eliem Therapeutics?

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

What sector is Eliem Therapeutics in?

Eliem Therapeutics is in the Healthcare sector

What industry is Eliem Therapeutics in?

Eliem Therapeutics is in the Biotechnology industry

What country is Eliem Therapeutics from?

Eliem Therapeutics is headquartered in United States

When did Eliem Therapeutics go public?

Eliem Therapeutics initial public offering (IPO) was on 10 August 2021

What is Eliem Therapeutics website?

https://eliemtx.com

Is Eliem Therapeutics in the S&P 500?

No, Eliem Therapeutics is not included in the S&P 500 index

Is Eliem Therapeutics in the NASDAQ 100?

No, Eliem Therapeutics is not included in the NASDAQ 100 index

Is Eliem Therapeutics in the Dow Jones?

No, Eliem Therapeutics is not included in the Dow Jones index

When was Eliem Therapeutics the previous earnings report?

No data

When does Eliem Therapeutics earnings report?

The next expected earnings date for Eliem Therapeutics is 14 November 2024